Navigation Links
Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
Date:6/19/2012

RALEIGH, N.C., June 19, 2012 /PRNewswire-iReach/ -- Scioderm today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of topical administration of SD-101, a dermal pharmaceutical in development for treatment of chronic wounds and lesions in children with various types of Epidermolysis Bullosa. The open label study was conducted in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. Eight children with EB (Simplex, RDEB, or Junctional EB) were enrolled and received daily administration by their caregivers of topically applied SD-101 over their entire body for a period of up to 3 months. The primary outcome measures were assessment of target wound area reduction and closure, and reduction in BSA coverage of lesions and erosions.  In the Phase II trial, SD-101 application resulted in closure of 85% of target chronic lesions, in addition to a 55% reduction in BSA coverage of lesions and erosions. SD-101 was well tolerated by the children, with daily administration up to 3 months.

SD-101 has also been designated as an orphan drug by the U.S. Food and Drug Administration for the treatment of Epidermolysis Bullosa (EB). Orphan drug designation provides a number of benefits to the company, including seven years of market exclusivity once SD-101 receives FDA clearance, assistance from the FDA with guiding SD-101 through the regulatory approval process, and waiver or partial payment of application fees and tax credits for clinical testing expenses conducted after orphan designation is received.

Robert Ryan, Ph.D., Chief Executive Officer of Scioderm added, "Epidermolysis Bullosa is a devastating disease. Our results from this trial indicate that SD-101 is a product candidate for treatment of the lesions and blistering on skin in children with EB, who have no other treatment alternatives, and it appears to have a favorable safety profile. We believe these data support the use of
'/>"/>

SOURCE Scioderm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Canada-based Radimetrics Announces Expansion to Scotland
2. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
3. American Oriental Bioengineering Announces Appointment of Audit Committee Chairman
4. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
5. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
6. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
7. Zimmer Announces Quarterly Dividend for Second Quarter of 2012
8. American Oriental Bioengineering Announces Change of Independent Auditors
9. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
10. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
11. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 , ... provide insight into treatment and outcomes of patients ... --   Data from nearly 12,500 ... the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic ... for atrial fibrillation (AF) patients remain sub-optimal despite ...
(Date:9/2/2014)... BARCELONA, Spain , September 2, 2014 ... treatment decisions, including patients, quality of life and treatment ... [ 2 ]   ... ESC Congress 2014, 02 September 2014, ... year results of the PREvention oF thromboembolic events-European Registry ...
(Date:9/2/2014)... CHARLOTTE, N.C. , Sept. 2, 2014 /PRNewswire/ ... today announced a partnership with the American Association ... professional association of respiratory care specialists. Edison Nation ... individuals and small business to commercialize their innovation ... professional association,s community of more than 50,000 respiratory ...
Breaking Medicine Technology:Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3
... Society of Clinical Oncology,s ... Genitourinary Symposium -, ... (Nasdaq: DNDN ) today presented data,demonstrating the correlation of ... active cellular immunotherapy,for hormone-refractory prostate cancer, with overall survival. This ...
... Confirm the Benefit Avastin Brings to ... Patients With Breast Cancer., BASEL, ... in metastatic breast cancer investigating Avastin,(bevacizumab) in combination with docetaxel chemotherapy ... patients,live without their disease advancing., The findings come from the ...
Cached Medicine Technology:Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival 2Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival 3Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival 4Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint 2Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint 3
(Date:9/2/2014)... -- Two new studies further confirm the health benefits ... breast-fed have a lower risk of ear, throat and ... finds a similar trend when it comes to allergies. ... in the immediate newborn period," said Dr. Jennifer Wu, ... City. She was not involved in the new studies. ...
(Date:9/2/2014)... -- Melatonin supplements did not reduce delirium in seniors ... found. Many older hospital patients experience the sudden, ... their normal sleep-wake cycle. A lack of the hormone ... but there has been little research into whether melatonin ... 378 patients, average age 84, who had hip fracture ...
(Date:9/2/2014)... leading group of oncologists has released updated guidelines for ... cancer. HER2-negative breast tumors include cancers that ... the American Society of Clinical Oncology (ASCO) explained Tuesday ... of women with advanced breast cancer have HER2-negative tumors, ... aim is to improve both the length and quality ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- As the Ebola outbreak continues to ... experts from the United States and the United Nations ... stem history,s biggest outbreak of the often-fatal virus. ... Disease Control and Prevention, said that without a greater ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
Breaking Medicine News(10 mins):Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Residency training predicts physicians' ability to practice conservatively 2
... , NEW YORK, Aug. 31 You may ... Massapequa, NY is a rare breed. He,s also a rare blood ... dedicated blood donor. , , Make that a VERY ... volunteer whole blood donation, the most on record for New York Blood ...
... FAIRFAX, Va., Aug. 31 The Office of National ... Services (HHS) issued key considerations and challenges for HIE implementation ... Title XIII funding document. , , ... Privacy and security of health information, including ...
... , , PHOENIX, Aug. 31 ... healthcare technology solutions for the ambulatory sector, announced today ... (NHIN), which is being developed to provide a secure, ... others involved in supporting healthcare. Noteworthy was one of ...
... 6 months of age, optometrists say , MONDAY, Aug. ... exam to their children,s back-to-school list, experts say. ... school without ever having an eye examination, even though ... , According to the American Optometric Association,s 2009 survey, ...
... identified a serious and previously misunderstood contaminant that ... into question. In a report published in the ... Leukocyte Biology ( http://www.jleukbio.org ), they show ... blood pressure in ailing patients also contains substances ...
... movie Gattaca, Ethan Hawke stars as a man with "inferior ... future. The 1997 film illustrates the very real fear ... information could be used negatively against us. Last year, ... way DNA data is made publicly available, health institutes in ...
Cached Medicine News:Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 2Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 3Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 4Health News:Edmond Scientific Company Rallies as Certifications & Assessments (C&A) Provider for HIEs Pursuing ARRA-ONC Grants 2Health News:Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability 2Health News:Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability 3Health News:Is Eye Exam on Your Back-to-School List? 2Health News:Are intravenous treatments safe? New research raises doubts 2Health News:Open source DNA 2Health News:Open source DNA 3
The Triage® Parasite Panel is an enzyme immunoassay used for the detection of antigens specific for Giardia lamblia, Entamoeba histolytica/dispar and Cryptosporidium parvum in fresh or freshly fr...
... Urostym™ provides the most current ... including urinary and fecal incontinence. ... easily providing complete patient information ... Customer testimonials have proven Urostym™ ...
... affordable path to Sonesta flexibility. Three ... back adjustments. Packaged with basic accessories, ... of Sonesta add-ons, allowing you to ... needs; complete Sonesta flexibility at an ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
Medicine Products: